iPSC– tag –
-
RoslinCT and BlueRock Therapeutics Partner to Expand Supply of Clinical-Grade iPSC Lines, Supporting Cell Therapy Development
PharmaSource UK Overview RoslinCT has announced a strategic partnership with BlueRock Therapeutics to expand access to clinical-grade iPSC lines for cell therapy developers. This collaboration integrates BlueRock's high-quality clinical-... -
STEMCELL Technologies and CCRM Partner to Accelerate Cell Therapy Development by Expanding Access to Matched GMP/RUO iPSC Lines
Business Wire USA Overview STEMCELL Technologies and the Centre for Commercialization of Regenerative Medicine (CCRM) have announced a strategic partnership to expand access to high-quality human iPSC starting materials. This collaborati... -
Sana Biotechnology Advances Phase 1 Clinical Trial for Immunosuppression-Free iPSC-Derived Islet Cell Therapy UP421 for Type 1 Diabetes
AAII USA Overview Sana Biotechnology is actively progressing its Phase 1 clinical trial for UP421, an allogeneic islet cell product engineered with its Hypoimmune Platform (HIP) technology for type 1 diabetes, aiming to eliminate the nee... -
iPSC-Derived Off-the-Shelf CAR T Therapy FT819 Shows Promising Safety and Efficacy Signals for Treatment-Resistant Systemic Sclerosis at ISSCR 2026
News-Medical.Net - An AZoNetwork Site USA Overview Preliminary clinical data for FT819, an iPSC-derived CAR T-cell therapy targeting treatment-resistant systemic sclerosis, were presented at the ISSCR 2026 Annual Meeting. FT819 is manufa... -
First-in-Human Pluripotent Stem Cell-Derived Neural Stem Cell Therapy for Huntington’s Disease (Regen4HD) Reports Phase 1b/2a Updates at ISSCR 2026
PharmaTimes USA Overview Updates from the first-in-human Phase 1b/2a clinical trial of Regen4HD, a pluripotent stem cell-derived neural stem cell therapy for Huntington's disease, were presented at the ISSCR 2026 Annual Meeting. This lan... -
Fate Therapeutics to Present iPSC-Derived Cell Immunotherapy Pipeline Progress at Investor Conferences
Fate Therapeutics, Inc. USA Overview Fate Therapeutics announced its participation in several upcoming investor conferences during Q3 2026. The clinical-stage biopharmaceutical company focuses on developing innovative 'off-the-shelf' iPS... -
UniXell’s iPSC-Derived Parkinson’s Therapy UX-DA003 Cleared for US Clinical Trials by FDA
Parkinson's News Today USA Overview UniXell Biotechnology has received FDA Investigational New Drug (IND) clearance for UX-DA003, an allogeneic iPSC-derived dopaminergic neural progenitor cell therapy for Parkinson's disease, enabling th... -
KATU News: Experimental Gene Therapy Targeting Aging Cells Based on Yamanaka Factors Enters Early Glaucoma Trials
KATU News (YouTube) USA Overview According to KATU News, an experimental gene therapy inspired by Professor Shinya Yamanaka's Nobel Prize-winning iPSC research is targeting aging cells and holds the potential to open a new chapter in agi... -
Amerigo Scientific Unveils Advanced iPSC-Derived Cells to Propel Biomedical Research and Cell Therapy
24-7PressRelease.com (Amerigo Scientific発表) USA Overview Amerigo Scientific has launched a new portfolio of high-purity, iPSC-derived cells, including advanced reporter lines, aimed at accelerating biomedical research and cell therapy ... -
CAR-NK Cell Therapy for Solid Tumors: Promising Safety and Off-the-Shelf Potential Outpace CAR-T
Cell Reports Medicine (via PubMed) USA Overview A new review highlights chimeric antigen receptor (CAR)-modified natural killer (NK) cells as a promising immunotherapy strategy for solid tumor treatment. Compared to CAR-T cell therapy, C...
